New Lifetime High Reached By Sanofi (SNY)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Sanofi ( SNY) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Sanofi as such a stock due to the following factors:

  • SNY has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $68.0 million.
  • SNY has traded 4,127 shares today.
  • SNY is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in SNY with the Ticky from Trade-Ideas. See the FREE profile for SNY NOW at Trade-Ideas

More details on SNY:

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. The stock currently has a dividend yield of 2.4%. SNY has a PE ratio of 30.0. Currently there are 3 analysts that rate Sanofi a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for Sanofi has been 1.1 million shares per day over the past 30 days. Sanofi has a market cap of $147.4 billion and is part of the health care sector and drugs industry. Shares are up 4.1% year-to-date as of the close of trading on Wednesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Biotech Mailbag: Buy Dip in T2 Biosystems?

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Sanofi Has Good Potential Upside

European Pharma Companies Slip on MS Pricing Probe